AVITA Medical Presents First Clinical Data of RECELL GO in the UK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2026
0mins
AVITA Medical announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom at the 2026 British Burn Association (BBA) Annual Meeting in Nottingham, U.K. The presentation, titled "First U.K. Clinical Experience of RECELL GO, an Automated Autologous Cell Harvesting Device, in Burn Surgery: A Case Series," reports outcomes from 17 patients treated at Stoke Mandeville Hospital, one of the U.K.'s leading specialist burn units. Investigators evaluated the use of RECELL GO, AVITA Medical's next-generation automated system for preparing RECELL Spray-On Skin Cells, across a range of burn and reconstructive procedures. In the U.K. case series, all patients successfully received RECELL Spray-On Skin Cells prepared using RECELL GO, either alone or in conjunction with meshed split-thickness skin grafts. Investigators reported uncomplicated donor-site healing, complete graft take, and successful patient discharge without complications. The authors also noted workflow benefits, including reduced procedural variability, improved consistency of cell preparation, and greater operating room efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCEL
Wall Street analysts forecast RCEL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.670
Low
3.00
Averages
4.25
High
5.50
Current: 4.670
Low
3.00
Averages
4.25
High
5.50
About RCEL
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AVITA Medical Hosts Investor Webinar on May 20, 2026
- Investor Webinar: AVITA Medical is set to host an investor webinar on May 20, 2026, at 4:00 PM Pacific Time, featuring CEO Cary Vance and CFO David O'Toole discussing Q1 2026 financial and business results, which is expected to attract significant investor interest.
- Interactive Q&A Session: The webinar will include a Q&A segment where participants can submit questions via the registration page, enhancing interaction between investors and management, thereby increasing transparency and trust.
- Melbourne Investor Discussion: Additionally, AVITA Medical will hold an investor discussion in Melbourne on May 21, 2026, at 4:00 PM AEST, where Cary Vance will converse with Michael Woods, CEO of Newburyport Partners, discussing the company's commercialization progress and execution priorities.
- Product Innovation and Market Expansion: AVITA Medical's RECELL® technology, approved by the FDA for treating thermal burns and trauma wounds, is expected to further solidify the company's leadership in the acute wound care market, improving clinical outcomes and accelerating patient recovery.
See More
AVITA Medical Q1 2026 Earnings Report Analysis
- Revenue Growth: AVITA Medical reported approximately $19.3 million in revenue for Q1 2026, reflecting a 4% year-over-year increase and a 10% sequential growth, indicating improved business stability and operational cadence, thereby enhancing market confidence.
- Gross Margin Decline: The gross margin for Q1 decreased to 81.7% from 84.7% in the prior year, primarily due to required inventory reserves and product mix changes, which may impact future profitability.
- Net Loss Improvement: The company reported a net loss of $10.6 million, or $0.35 per share, an improvement from the previous year's loss of $13.9 million or $0.53 per share, indicating progress in cost control measures.
- Long-Term Agreement Signed: AVITA Medical secured a new long-term agreement with BARDA, expected to provide approximately $3.9 million in recurring revenue over the next 10 years, reinforcing the importance of its products in emergency preparedness and further supporting its revenue diversification strategy.
See More
AVITA Medical Q1 2026 Earnings Call Insights
- Revenue Growth: AVITA Medical reported approximately $19.3 million in revenue for Q1 2026, reflecting a 4% year-over-year increase and a 10% sequential rise, while reaffirming its full-year revenue guidance of $80 million to $85 million, indicating positive operational improvements.
- Reimbursement Improvement: All seven Medicare Administrative Contractors have published payment rates for clinical use, driving a gradual return to utilization patterns that align with procedural demand, particularly enhancing the market for RECELL GO mini and smaller burn applications, thus increasing predictability in demand.
- Long-term Agreement Signed: The company announced a new long-term agreement with BARDA to support U.S. burn emergency preparedness, which is expected to generate around $3.9 million in stable revenue, further reinforcing RECELL's role in mass casualty response scenarios.
- Gross Margin Changes: The gross profit margin for the quarter was 81.7%, down from 84.7% in the prior year, while total operating expenses decreased by 11% to $24.5 million, despite a net loss of $10.6 million, showcasing the company's efforts in cost management.
See More
AVITA Medical Q1 Earnings Announcement Scheduled
- Earnings Release Date: AVITA Medical (RCEL) is set to announce its Q1 earnings on May 14th after market close, with a consensus EPS estimate of -$0.27, reflecting a significant year-over-year increase of 49.1%, indicating efforts to improve profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $18.64 million, representing a modest year-over-year growth of 0.8%, which, while limited, suggests a stable performance in the market that could lay the groundwork for future growth.
- Performance Against Estimates: Over the past year, AVITA has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, highlighting the company's volatility in financial forecasting and potential market confidence.
- Estimate Revision Dynamics: In the last three months, there has been one upward revision and no downward revisions for EPS estimates, while revenue estimates saw one downward revision, indicating a cautious market outlook that may affect investor confidence.
See More
AVITA MEDICAL INC APPOINTS CARY VANCE AS CEO
Leadership Announcement: Avita Medical has appointed Cary Vance as the new Chief Executive Officer.
Company Overview: Avita Medical is focused on developing innovative regenerative medicine solutions.
See More
AVITA Medical Appoints Cary Vance as CEO Following Interim Role
- Leadership Change: AVITA Medical has appointed Cary Vance as CEO, effective immediately, after serving in an interim capacity since October 2025, indicating the board's commitment to stable leadership during a critical growth phase.
- Board Restructuring: Concurrently, Jan Stern Reed has been named chair of the board, reflecting an enhancement in the company's governance structure aimed at improving decision-making efficiency and strategic execution.
- Market Focus: Vance emphasized that the company will concentrate on scaling the adoption of its products and driving consistent performance in the acute wound care market, highlighting AVITA's strategic intent in a rapidly growing healthcare sector.
- Contract Win: AVITA Medical recently secured a BARDA contract worth up to $25.5 million, which not only provides financial backing but may also accelerate the promotion and application of its products in the market.
See More
AVITA Medical Hosts Investor Webinar on May 20, 2026
- Investor Webinar: AVITA Medical is set to host an investor webinar on May 20, 2026, at 4:00 PM Pacific Time, featuring CEO Cary Vance and CFO David O'Toole discussing Q1 2026 financial and business results, which is expected to attract significant investor interest.
- Interactive Q&A Session: The webinar will include a Q&A segment where participants can submit questions via the registration page, enhancing interaction between investors and management, thereby increasing transparency and trust.
- Melbourne Investor Discussion: Additionally, AVITA Medical will hold an investor discussion in Melbourne on May 21, 2026, at 4:00 PM AEST, where Cary Vance will converse with Michael Woods, CEO of Newburyport Partners, discussing the company's commercialization progress and execution priorities.
- Product Innovation and Market Expansion: AVITA Medical's RECELL® technology, approved by the FDA for treating thermal burns and trauma wounds, is expected to further solidify the company's leadership in the acute wound care market, improving clinical outcomes and accelerating patient recovery.
See More
AVITA Medical Q1 2026 Earnings Report Analysis
- Revenue Growth: AVITA Medical reported approximately $19.3 million in revenue for Q1 2026, reflecting a 4% year-over-year increase and a 10% sequential growth, indicating improved business stability and operational cadence, thereby enhancing market confidence.
- Gross Margin Decline: The gross margin for Q1 decreased to 81.7% from 84.7% in the prior year, primarily due to required inventory reserves and product mix changes, which may impact future profitability.
- Net Loss Improvement: The company reported a net loss of $10.6 million, or $0.35 per share, an improvement from the previous year's loss of $13.9 million or $0.53 per share, indicating progress in cost control measures.
- Long-Term Agreement Signed: AVITA Medical secured a new long-term agreement with BARDA, expected to provide approximately $3.9 million in recurring revenue over the next 10 years, reinforcing the importance of its products in emergency preparedness and further supporting its revenue diversification strategy.
See More
AVITA Medical Q1 2026 Earnings Call Insights
- Revenue Growth: AVITA Medical reported approximately $19.3 million in revenue for Q1 2026, reflecting a 4% year-over-year increase and a 10% sequential rise, while reaffirming its full-year revenue guidance of $80 million to $85 million, indicating positive operational improvements.
- Reimbursement Improvement: All seven Medicare Administrative Contractors have published payment rates for clinical use, driving a gradual return to utilization patterns that align with procedural demand, particularly enhancing the market for RECELL GO mini and smaller burn applications, thus increasing predictability in demand.
- Long-term Agreement Signed: The company announced a new long-term agreement with BARDA to support U.S. burn emergency preparedness, which is expected to generate around $3.9 million in stable revenue, further reinforcing RECELL's role in mass casualty response scenarios.
- Gross Margin Changes: The gross profit margin for the quarter was 81.7%, down from 84.7% in the prior year, while total operating expenses decreased by 11% to $24.5 million, despite a net loss of $10.6 million, showcasing the company's efforts in cost management.
See More
AVITA Medical Q1 Earnings Announcement Scheduled
- Earnings Release Date: AVITA Medical (RCEL) is set to announce its Q1 earnings on May 14th after market close, with a consensus EPS estimate of -$0.27, reflecting a significant year-over-year increase of 49.1%, indicating efforts to improve profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $18.64 million, representing a modest year-over-year growth of 0.8%, which, while limited, suggests a stable performance in the market that could lay the groundwork for future growth.
- Performance Against Estimates: Over the past year, AVITA has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, highlighting the company's volatility in financial forecasting and potential market confidence.
- Estimate Revision Dynamics: In the last three months, there has been one upward revision and no downward revisions for EPS estimates, while revenue estimates saw one downward revision, indicating a cautious market outlook that may affect investor confidence.
See More
AVITA MEDICAL INC APPOINTS CARY VANCE AS CEO
Leadership Announcement: Avita Medical has appointed Cary Vance as the new Chief Executive Officer.
Company Overview: Avita Medical is focused on developing innovative regenerative medicine solutions.
See More
AVITA Medical Appoints Cary Vance as CEO Following Interim Role
- Leadership Change: AVITA Medical has appointed Cary Vance as CEO, effective immediately, after serving in an interim capacity since October 2025, indicating the board's commitment to stable leadership during a critical growth phase.
- Board Restructuring: Concurrently, Jan Stern Reed has been named chair of the board, reflecting an enhancement in the company's governance structure aimed at improving decision-making efficiency and strategic execution.
- Market Focus: Vance emphasized that the company will concentrate on scaling the adoption of its products and driving consistent performance in the acute wound care market, highlighting AVITA's strategic intent in a rapidly growing healthcare sector.
- Contract Win: AVITA Medical recently secured a BARDA contract worth up to $25.5 million, which not only provides financial backing but may also accelerate the promotion and application of its products in the market.
See More
